SCHEMBL3407111

SCHEMBL3407111

O=C(Cc1ccc(F)cc1)Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
GAA P10253 2/20 0.42
ROCK2 O75116 3/20 0.42
NMT2 O60551 1/20 0.42
NMT1 P30419 1/20 0.42
MAPK1 P28482 1/20 0.41
ROCK1 Q13464 2/20 0.40
HDAC1 Q13547 1/20 0.40
PFKFB3 Q16875 1/20 0.40
MCHR1 Q99705 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3398554 0.88 NPC1 (0.52) NPC1RAB9AALDH1A1MAPTMEN1
SCHEMBL4106104 0.86 HTR2C (0.46) NPC1RAB9AMAPTSMN1; SMN2MEN1
SCHEMBL4114887 0.86 NPC1 (0.41) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL3413128 0.85 PLAU (0.41) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL4100049 0.83 SMN1; SMN2 (0.47) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL4115121 0.83 NPY5R (0.43) KDM4ENPC1RAB9AMAPTMEN1
SCHEMBL3401343 0.83 KMT2A (0.56) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL3415639 0.83 NPC1 (0.47) KDM4ENPC1RAB9AHPGDSMN1; SMN2
SCHEMBL2242730 0.82 ROCK2 (0.42) KDM4ERAB9AALDH1A1HPGDMAPT
SCHEMBL3414984 0.82 AURKA (0.41) NPC1MAPTMEN1KMT2APFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP disclosed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B KDM4E 1411/4885NPC1 2445/4885RAB9A 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.